Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome

Genes, Brain and Behavior

Volumn 11, Issue 3, 2012, Pages 332-341

  Hoeffer, C A ^a,b   Sanchez, E ^c   Hagerman, R J ^d,e   Mu, Y ^c   Nguyen, D V ^c   Wong, H ^a   Whelan, A M ^b   Zukin, R S ^f   Klann, E ^a   Tassone, F ^c,e  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CYFIP1; CYFIP2; Fragile X; MTOR; Phosphorylation

Indexed keywords

CYTOPLASMIC FMR1 INTERACTING PROTEIN 2; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; P70 RIBOSOMAL SUBUNIT 6 KINASE; PHOSPHOTRANSFERASE; PROTEIN; PROTEIN HYDROLYSATE; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TISSUE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRAGILE X SYNDROME; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA ISOLATION; RNA TRANSCRIPTION; SCHOOL CHILD; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UP-REGULATION; YOUNG ADULT;

EUKARYOTA; MAMMALIA;

EID: 84859420878     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/j.1601-183X.2012.00768.x     Document Type: Article

References (68)

1. APA (2000) Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition-Text Revision (DSMIV-TR). American Psychiatric Association, Washington DC.
2. Avni, D., Biberman, Y. & Meyuhas, O. (1997) The 5' terminal oligopyrimidine tract confers translational control on TOP mRNAs in a cell type- and sequence context-dependent manner. Nucleic Acids Res 25, 995-1001.
3. Bagni, C. & Greenough, W.T. (2005) From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 6, 376-387.
4. Brown, V., Jin, P., Ceman, S., Darnell, J.C., O'Donnell, W.T., Tenenbaum, S.A., Jin, X., Feng, Y., Wilkinson, K.D., Keene, J.D., Darnell, R.B. & Warren, S.T. (2001) Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107, 477-487.
5. Burnett, P.E., Barrow, R.K., Cohen, N.A., Snyder, S.H. & Sabatini, D.M. (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 95, 1432-1437.
6. Comery, T.A., Harris, J.B., Willems, P.J., Oostra, B.A., Irwin, S.A., Weiler, I.J. & Greenough, W.T. (1997) Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A 94, 5401-5404.
7. Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y., Mele, A., Fraser, C.E., Stone, E.F., Chen, C., Fak, J.J., Chi, S.W., Licatalosi, D.D., Richter, J.D. & Darnell, R.B. (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261.
8. de Vries, B.B. & Niermeijer, M.F. (1994) The Prader-Willi-like phenotype in fragile X patients: a designation facilitating clinical (and molecular) differential diagnosis. J Med Genet 31, 820.
9. de Vries, B.B., Fryns, J.P., Butler, M.G., Canziani, F., Wesby-van Swaay, E., van Hemel, J.O., Oostra, B.A., Halley, D.J. & Niermeijer, M.F. (1993) Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. J Med Genet 30, 761-766.
10. Demark, J.L., Feldman, M.A. & Holden, J.J.A. (2003) Behavioral relationship between autism and fragile X syndrome. Am J Ment Retard 108, 314-326.
11. Derivery, E., Lombard, B., Loew, D. & Gautreau, A. (2009) The Wave complex is intrinsically inactive. Cell Motil Cytoskeleton 66, 777-790.
12. Derivery, E. & Gautreau, A. (2010) Generation of branched actin networks: assembly and regulation of the N-WASP and WAVE molecular machines. Bioessays 32, 119-131.
13. Dwivedi, Y., Rizavi, H.S., Conley, R.R. & Pandey, G.N. (2006) ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol psychiatry 11, 86-98.
14. Filipovic-Sadic, S., Sah, S., Chen, L., Krosting, J., Sekinger, E., Zhang, W., Hagerman, P.J., Stenzel, T.T., Hadd, A.G., Latham, G.J. & Tassone, F. (2010) A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem 56, 399-408.
15. Flynn, A. & Proud, C.G. (1995) Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells. J Biol Chem 270, 21684-21688.
16. Fryns, J.P., Haspeslagh, M., Dereymaeker, A.M., Volcke, P. & Berghe, Van den H. (1987) A peculiar subphenotype in the fra(X) syndrome: extreme obesity-short stature-stubby hands and feet-diffuse hyperpigmentation. Further evidence of disturbed hypothalamic function in the fra(X) syndrome? Clin Genet 32, 388-392.
17. Fu, Y.H., Kuhl, D.P., Pizzuti, A., Pieretti, M., Sutcliffe, J.S., Richards, S., Verkerk, A.J., Holden, J.J., Fenwick, R.G. Jr, Warren, S.T., Oostra, B.A., Nelson, D.L. & Caskey, C.T. (1991) Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67, 1047-1058.
18. Gingras, A.C., Raught, B. & Sonenberg, N. (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68, 913-963.
19. Greco, C.M., Navarro, C.S., Hunsaker, M.R., Maezawa, I., Shuler, J.F., Tassone, F., Delany, M., Au, J.W., Berman, R.F., Jin, L.W., Schumann, C., Hagerman, P.J. & Hagerman, R.J. (2011) Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome. Mol Autism 2, 2.
20. Hagerman, R.J. & Hagerman, P.J. (2002) The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev 12, 278-283.
21. Hagerman, R., Hoem, G. & Hagerman, P. (2010) Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol Autism 1, 12.
22. Harris, S.W., Hessl, D., Goodlin-Jones, B., Ferranti, J., Bacalman, S., Barabato, I., Tassone, F., Hagerman, P.J., Herman, K. & Hagerman, R.J. (2008) Autism profiles of males with fragile X syndrome. Am J Ment Retard 113, 427-438.
23. Hatton, D.D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D.B. Jr, Roberts, J.E. & Mirrett, P. (2006) Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet 140, 1804-1813.
24. Hou, L., Antion, M.D., Hu, D., Spencer, C.M., Paylor, R. & Klann, E. (2006) Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51, 441-454.
25. Hunsaker, M.R., Greco, C.M., Tassone, F., Berman, R.F., Willemsen, R., Hagerman, R.J. & Hagerman, P.J. (2011) Rare intranuclear inclusions in the brains of 3 older adult males with fragile X syndrome: implications for the spectrum of fragile X-associated disorders. J Neuropathol Exp Neurol 70, 462-469.
26. Irwin, S.A., Galvez, R. & Greenough, W.T. (2000) Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10, 1038-1044.
27. Jacinto, E. & Lorberg, A. (2008) TOR regulation of AGC kinases in yeast and mammals. Biochem J 410, 19-37.
28. Jackson, R.S. II, Cho, Y.J., Stein, S. & Liang, P. (2007) CYFIP2, a direct p53 target, is leptomycin-B sensitive. Cell Cycle 6, 95-103.
29. Jacquemont, S., Hagerman, R.J., Hagerman, P.J. & Leehey, M.A. (2007) Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 6, 45-55.
30. Kaufmann, W.E., Cortell, R., Kau, A.S., Bukelis, I., Tierney, E., Gray, R.M., Cox, C., Capone, G.T. & Stanard, P. (2004) Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet 129A, 225-234.
31. Klann, E. & Dever, T.E. (2004) Biochemical mechanisms for translational regulation in synaptic plasticity. Nat Rev Neurosci 5, 931-942.
32. Levanon, E.Y., Hallegger, M., Kinar, Y., Shemesh, R., Djinovic-Carugo, K., Rechavi, G., Jantsch, M.F. & Eisenberg, E. (2005) Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res 33, 1162-1168.
33. Loesch, D.Z., Bui, Q.M., Dissanayake, C., Clifford, S., Gould, E., Bulhak-Paterson, D., Tassone, F., Taylor, A.K., Hessl, D., Hagerman, R. & Huggins, R.M. (2007) Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci Biobehav Rev 31, 315-326.
34. Lord, C., Rutter, M., DiLavore, P.C. & Risi, S. (1999) Autism Diagnostic Observation Schedule. Western Psychological Services, Los Angeles, CA.
35. Mayne, M., Moffatt, T., Kong, H., McLaren, P.J., Fowke, K.R., Becker, K.G., Namaka, M., Schenck, A., Bardoni, B., Bernstein, C.N. & Melanson, M. (2004) CYFIP2 is highly abundant in CD4+ cells from multiple sclerosis patients and is involved in T cell adhesion. Eur J Immunol 34, 1217-1227.
36. McKendrick, L., Pain, V.M. & Morley, S.J. (1999) Translation initiation factor 4E. Int J Biochem Cell Biol 31, 31-35.
37. Miyashiro, K.Y., Beckel-Mitchener, A., Purk, T.P., Becker, K.G., Barret, T., Liu, L., Carbonetto, S., Weiler, I.J., Greenough, W.T. & Eberwine, J. (2003) RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 37, 417-431.
38. Mongroo, P.S., Noubissi, F.K., Cuatrecasas, M., Kalabis, J., King, C.E., Johnstone, C.N., Bowser, M.J., Castells, A., Spiegelman, V.S. & Rustgi, A.K. (2011) IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. Cancer Res 71, 2172-2182.
39. Napoli, I., Mercaldo, V., Boyl, P.P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., Witke, W., Costa-Mattioli, M., Sonenberg, N., Achsel, T. & Bagni, C. (2008) The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134, 1042-1054.
40. Nishimura, Y., Martin, C.L., Vazquez-Lopez, A., Spence, S.J., Alvarez-Retuerto, A.I., Sigman, M., Steindler, C., Pellegrini, S., Schanen, N.C., Warren, S.T. & Geschwind, D.H. (2007) Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum Mol Genet 16, 1682-1698.
41. Nowicki, S.T., Tassone, F., Ono, M.Y., Ferranti, J., Croquette, M.F., Goodlin-Jones, B. & Hagerman, R.J. (2007) The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr 28, 133-138.
42. Pieretti, M., Zhang, F.P., Fu, Y.H., Warren, S.T., Oostra, B.A., Caskey, C.T. & Nelson, D.L. (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817-822.
43. Reynolds, T.H.t., Bodine, S.C. & Lawrence, J.C. Jr (2002) Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 277, 17657-17662.
44. Rogers, S.J., Wehner, D.E. & Hagerman, R. (2001) The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr 22, 409-417.
45. Rutter, M., Le Couteur, A. & Lord, C. (2003a) Autism Diagnostic Interview-Revised (ADI-R). Western Psychological Services, Los Angeles, CA.
46. Rutter, M., Bailey, A., Berument, S.K., Lord, C. & Pickles, A. (2003b) Social Communication Questionnaire (SCQ). Western Psychological Services, Los Angeles, CA.
47. Saller, E., Tom, E., Brunori, M., Otter, M., Estreicher, A., Mack, D.H. & Iggo, R. (1999) Increased apoptosis induction by 121F mutant p53. EMBO J 18, 4424-4437.
48. Schenck, A., Bardoni, B., Moro, A., Bagni, C. & Mandel, J.L. (2001) A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci U S A 98, 8844-8849.
49. Schenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J.L. & Giangrande, A. (2003) CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron 38, 887-898.
50. Schenck, A., Qurashi, A., Carrera, P., Bardoni, B., Diebold, C., Schejter, E., Mandel, J.L. & Giangrande, A. (2004) WAVE/SCAR, a multifunctional complex coordinating different aspects of neuronal connectivity. Dev Biol 274, 260-270.
51. Schrander-Stumpel, C., Meinecke, P., Wilson, G., Gillessen-Kaesbach, G., Tinschert, S., Konig, R., Philip, N., Rizzo, R., Schrander, J., Pfeiffer, L., Maat-Kievit, A., van der Burgt, L., van Essen, T., Latta, E., Hillig, U., Verloes, A., Journel, H. & Fryns, J.P. (1994) The Kabuki (Niikawa-Kuroki) syndrome: further delineation of the phenotype in 29 non-Japanese patients. Eur J Pediatr 153, 438-445.
52. Sekulic, A., Hudson, C.C., Homme, J.L., Yin, P., Otterness, D.M., Karnitz, L.M. & Abraham, R.T. (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60, 3504-3513.
53. Sharma, A., Hoeffer, C.A., Takayasu, Y., Miyawaki, T., McBride, S.M., Klann, E. & Zukin, R.S. (2010) Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 30, 694-702.
54. Sokoloff, L. (1981) Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab 1, 7-36.
55. Sparrow, S.S., Cicchetti, D.V. & Balla, D.A. (2005) Vineland Adaptive Behavior Scales, 2nd edn. AGS Publishing, Circle Pines, MN.
56. Suetsugu, S., Yamazaki, D., Kurisu, S. & Takenawa, T. (2003) Differential roles of WAVE1 and WAVE2 in dorsal and peripheral ruffle formation for fibroblast cell migration. Dev Cell 5, 595-609.
57. Tahirovic, S., Hellal, F., Neukirchen, D., Hindges, R., Garvalov, B.K., Flynn, K.C., Stradal, T.E., Chrostek-Grashoff, A., Brakebusch, C. & Bradke, F. (2010) Rac1 regulates neuronal polarization through the WAVE complex. J Neurosci 30, 6930-6943.
58. Takenawa, T. & Suetsugu, S. (2007) The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol 8, 37-48.
59. Tassone, F., Hagerman, R.J., Loesch, D.Z., Lachiewicz, A., Taylor, A.K. & Hagerman, P.J. (2000) Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet 94, 232-236.
60. Tassone, F., Pan, R., Amiri, K., Taylor, A.K. & Hagerman, P.J. (2008) A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn 10, 43-49.
61. Utari, A., Adams, E., Berry-Kravis, E., Chavez, A., Scaggs, F., Ngotran, L., Boyd, A., Hessl, D., Gane, L.W., Tassone, F., Tartaglia, N., Leehey, M.A. & Hagerman, R.J. (2010) Aging in fragile X syndrome. J Neurodev Disord 2, 70-76.
62. Verkerk, A.J., Pieretti, M., Sutcliffe, J.S. et al. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914.
63. Waskiewicz, A.J., Johnson, J.C., Penn, B., Mahalingam, M., Kimball, S.R. & Cooper, J.A. (1999) Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 19, 1871-1880.
64. Wechsler, D. (1999) Wechsler Abbreviated Scale of Intelligence (WASI). Harcourt Assessment, Inc., San Antonio, TX.
65. Wechsler, D. (2002) Wechsler Preschool and Primary Scale of Intelligence, 3rd edn. The Psychological Corporation, San Antonio, TX.
66. Wechsler, D. (2003) Wechsler Intelligence Scale for Children, 4th edn. Harcourt Assessment, Inc., San Antonio, TX.
67. Weng, N., Weiler, I.J., Sumis, A., Berry-Kravis, E. & Greenough, W.T. (2008) Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am J Med Genet 147B, 1253-1257.
68. Yu, S., Pritchard, M., Kremer, E., Lynch, M., Nancarrow, J., Baker, E., Holman, K., Mulley, J.C., Warren, S.T., Schlessinger, D., Sutherland, G.R. & Richard, R.I. (1991) Fragile X genotype characterized by an unstable region of DNA. Science 252, 1179-1181.